Do transfeminine (male-to-female) patients require estrogen therapy?

Yes, transfeminine patients require estrogen therapy as the cornerstone of feminizing hormone treatment.

Estrogen is medically necessary for male-to-female transgender patients seeking physical feminization and is recommended as standard care in combination with anti-androgen therapy 1.

Rationale for Estrogen Therapy

The hormone regimen for transfeminine individuals centers on estrogen administration to induce feminizing physical changes and improve quality of life. Estrogen therapy has been consistently shown to:

• Reduce gender dysphoria and improve mental well-being 2, 3
• Induce desired physical changes including breast development (onset 3-6 months, maximum 2-3 years), body fat redistribution, decreased muscle mass, and skin softening 1
• Improve overall quality of life, which is considered a primary outcome justifying its medical necessity 4

Treatment Approach

Combination Therapy is Standard

Estrogen alone is insufficient. The Endocrine Society guidelines explicitly state that most published clinical studies report using an antiandrogen in conjunction with estrogen 1. The antiandrogens serve to:

• Suppress endogenous testosterone to female range (<55 ng/dL)
• Enable estrogen therapy to have its fullest feminizing effect
• Achieve optimal physical transition outcomes

Specific Estrogen Formulations

Preferred options 1:

• 17β-estradiol (oral or transdermal) - can be monitored via serum levels
• Transdermal estrogen - preferred in older patients or those at higher thromboembolic risk
• Parenteral estrogen esters - alternative option

Avoid: Ethinyl estradiol and synthetic estrogens due to 20-fold increased risk of venous thromboembolism and inability to monitor serum levels 1

Target Hormone Levels

• Estradiol: 200 pg/mL (mean daily level for premenopausal women)
• Testosterone: <55 ng/dL (female range)

Anti-Androgen Options

Choose based on availability and patient factors 1:

• Spironolactone - inhibits testosterone secretion and androgen receptor binding (commonly used in US)
• Cyproterone acetate - progestational compound with anti-androgenic properties (widely used in Europe, but note recent concerns about risks 5)
• GnRH agonists (e.g., goserelin acetate) - effective with low adverse reaction incidence

Avoid: Flutamide - has liver toxicity and unproven efficacy

Critical Safety Considerations

Thromboembolic Risk

• Venous thromboembolism is the most serious complication
• Screen for thrombophilia only if personal or family history of VTE 1
• Strongly encourage smoking cessation to reduce cardiovascular and thrombotic complications
• Do NOT routinely monitor D-dimer levels

Pre-Treatment Requirements

Before initiating estrogen 1:

1. Confirm diagnosis of gender dysphoria by mental health professional
2. Evaluate medical conditions that can be exacerbated by hormone therapy
3. Discuss risks/benefits thoroughly, especially in patients with diabetes, liver disease, or smoking history
4. Obtain informed consent regarding all risks and benefits

Monitoring Protocol

First year: Every 3 months
Ongoing: Once or twice yearly 1

Monitor:

• Serum estradiol and testosterone levels
• Prolactin levels (risk of macroprolactinoma)
• Cardiovascular risk factors
• Breast cancer screening per biological male guidelines
• Prostate screening per biological male guidelines

Common Pitfall to Avoid

Do not use estrogen monotherapy without anti-androgens - this is inadequate for achieving feminization goals and maintaining testosterone suppression. The evidence consistently shows combination therapy is the standard approach for optimal outcomes 1.